Build status - In Progress

An extended access program to assess long-term safety of bardoxolone methyl in patients with pulmonary hypertension

An extended access program to assess long-term safety of bardoxolone methyl in patients with pulmonary hypertension
Recruiting
99 years or below
All
Phase 3
6 participants needed
1 Location

Brief description of study

This is a Phase 3a, extended access program to assess long-term safety of bardoxolone methyl in patients with pulmonary hypertension. The purpose of this study is to provide or continue to provide bardoxolone methyl to eligible subjects who participated in the CATALYST study. The study will also collect ongoing safety and tolerability data of bardoxolone methyl.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Pulmonary Hypertension
  • Age: 99 years or below
  • Gender: All
Updated on 04 Aug 2024. Study ID: 828280

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center